Red Cedar Capital’s Novartis NVS Stock Holding History

Red Cedar Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$285K	Hold	3,140	–	–	0.18%	56
2022 Q3	$239K	Hold	3,140	–	–	0.16%	60
2022 Q2	$265K	Hold	3,140	–	–	0.18%	58
2022 Q1	$276K	Hold	3,140	–	–	0.17%	59
2021 Q4	$275K	Hold	3,140	–	–	0.16%	61
2021 Q3	$257K	Hold	3,140	–	–	0.16%	61
2021 Q2	$286K	Hold	3,140	–	–	0.18%	57
2021 Q1	$268K	Hold	3,140	–	–	0.18%	59
2020 Q4	$297K	Hold	3,140	–	–	0.22%	50
2020 Q3	$273K	Hold	3,140	–	–	0.24%	50
2020 Q2	$274K	Hold	3,140	–	–	0.25%	50
2020 Q1	$259K	Hold	3,140	–	–	0.26%	50
2019 Q4	$297K	Hold	3,140	–	–	0.23%	52
2019 Q3	$273K	Hold	3,140	–	–	0.22%	51
2019 Q2	$287K	Sell	3,140 -364	-10%	-$30.8K	0.24%	52
2019 Q1	$302K	Hold	3,504	–	–	0.26%	50
2018 Q4	$269K	Hold	3,504	–	–	0.26%	51
2018 Q3	$271K	Hold	3,504	–	–	0.24%	52
2018 Q2	$237K	Hold	3,504	–	–	0.21%	56
2018 Q1	$254K	Hold	3,504	–	–	0.23%	56
2017 Q4	$264K	Buy	+3,504	New	+$264K	0.22%	55

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Red Cedar Capital's NVS Position: Q4 2022 in Review

Red Cedar Capital held its Novartis (NVS) position steady in Q4 2022 at 3,140 shares worth $285K. The position accounts for 0.18% of the portfolio, ranked #56.

Red Cedar Capital first reported a position in NVS in Q4 2017 and has held it in 21 quarters since. The position peaked at $302K in Q1 2019. 1,182 funds tracked by Wall St. Rank hold NVS as of Q4 2022.

Red Cedar Capital held 3,140 shares of Novartis worth $285K as of Q4 2022.
Red Cedar Capital left its Novartis share count unchanged in Q4 2022.
Novartis made up 0.18% of Red Cedar Capital's portfolio in Q4 2022, its #56 holding.
Red Cedar Capital first reported a position in Novartis in Q4 2017 and has held it in 21 quarters since.
Red Cedar Capital's Novartis position peaked at $302K in Q1 2019.
1,182 funds tracked by Wall St. Rank held Novartis as of Q4 2022.

Based on Red Cedar Capital's 13F filing for Q4 2022, filed 6 Feb 2023.